Magnus Medical is a developer of brain stimulation technology to treat neuropsychiatric disorders, first participant An open-label optimization (OLO) clinical trial evaluated the efficacy of a neuromodulatory system using Saint Technology in the treatment of major depressive disorder (MDD).
According to the company, Saint Technology’s Magnus Neuromodulation System “uses structural and functional magnetic resonance imaging (MRI) to inform proprietary algorithms that identify the best anatomical brain targets for focused neurostimulation in patients with MDD.” The system is non-invasive and uses individually targeted stimulation to regions in the brain to treat MDD.
of study It is intended for patients with MDD who have failed previous antidepressant treatment. The study will be conducted at up to nine clinics across the United States and will enroll up to 1,000 adults who will be treated on an accelerated schedule of 10 sessions per day, 10 minutes of Saint Therapy treatment followed by 50 minutes of rest for five consecutive days.
“The OLO trial is the first multicenter study of the SAINT neuromodulation system, allowing a large sample of adults suffering from clinical depression to access a fast-acting, personalized treatment for treatment-resistant major depression,” said Brandon Benthley, M.D., Ph.D., co-founder and chief scientific officer of Magnus.
The trial expanded on results from a previous randomized controlled trial that showed encouraging results, with 79% of participants experiencing relief from severe depression after receiving SAINT treatment.
“Saint Therapy marks the beginning of a revolution in psychiatry. It is a rapid, effective, and personalized treatment that offers hope to patients who have failed to find relief from traditional approaches,” said David Calleon, M.D., attending physician at Acacia Mental Health in Sunnyvale, California, who was the first to enroll in the OLO study. Our clinic specializes in caring for the most difficult and most desperate patients with depression by providing the best treatments available. We are beginning to enroll participants and would like to know if the overwhelmingly positive results we saw in our first clinical trial at Stanford University translate to our patients as well.”
Magnus said he expects clinical trial results to be available in 2027.
